Trendlines Group Ltd. · SGX:42T
Trendlines — ViAqua Therapeutics — Seed Pitch Deck (December 2016)
29 slides from Trendlines's pitch deck, December 2016
Slide 1: Shai Ufaz, Ph.D., Co-CEO | December 2016
Shai Ufaz, Ph.D., Co-CEO| December| 2016 1
Slide 2: Shellfish Market $36B Market Value Per Year
SHELLFISH MARKET $36B MARKET VALUE PER YEAR Food and Agriculture Organization (FAO 2016) Shellfish farming (mainly shrimp and prawns) is an enormous industry. 2
Slide 3: Shellfish Market Annual Growth Rate
Shrimp Aquaculture production SHELLFISH MARKET (2016, FAO and GOAL Surveys) Asia 89% Americas 10% BY Africa 0.2% CONTINENT 10% $� B MARKET VALUE PER YEAR Shrimp Aquaculture production by major producers in Asia (2016, FAO and GOAL Surveys) ANNUAL GROWTH RATE China 42% Indonesia 23% for the past deca
Slide 4: Shellfish Aquaculture: Industry Losses from Disease 20% = $7.2B
SHELLFISH AQUACULTURE (FAO, 2016) 55% Farmed 20% = $7.2B Industry Losses from Disease 4
Slide 5: Disease = Biggest Risk
SHELLFISH AQUACULTURE DISEASE = BIGGEST RISK Undermines market development 5
Slide 6: Shrimp Industry Losses
SHRIMP INDUSTRY LOSSES Jan. 2015 Dec. 2016 April 2014 What can we do about it today? …… 6
Slide 7: No Current Treatment!
NO CURRENT TREATMENT! Today, there are no means to prevent or treat viral diseases in shrimp. When a disease appears, it wipes out the pond within 7-10 days. Quote 7
Slide 8: Innovative Approach
INNOVATIVE APPROACH 8
Slide 9: RNA Interference
RNA INTERFERENCE Therapeutic approach: silencing key genes of a virus RNA acts as a TARGET DESIGNATOR. It marks the viral RNA and tells using a method called RNA interference (RNAi) the cell it has an intruder and should prepare to fight it. This process is similar to vaccination 1 RNA delivered to
Slide 10: RNAi Very Promising Approach for Treating Shrimp Viruses
RNAi VERY PROMISING APPROACH FOR TREATING SHRIMP VIRUSES Injecting the shrimp one by one is not a feasible method for wide use in shrimp aquaculture. RNAi has very promising results on shrimp viruses when tested with injection But try to treat 20 tons of shrimps, one-by-one, using a syringe… 10
Slide 11: The Real Challenge: Delivery by Feed
THE REAL CHALLENGE DELIVERY DELIVERY BY FEED ViAqua Platform technology tailored for aquaculture 11
Slide 12: The Concept: Nanoparticle Carrier
THE CONCEPT NANO PARTICLE CARRIER For each virus we - (1) select and produce an effective RNA sequence, and (2) combine the RNA strands with our specially developed carrier Non GMO Non Hormone No antibiotic component Feed-grade formulation Safe for both shrimp and humans Can effect multiple virus st
Slide 13: The Entire Process
THE ENTIRE PROCESS Aquatic Environment Digestive System Cell Membrane Nanoparticles (NPs) are pass from the aquatic environment, into the cells where the RNA is released integrated into feed….. through the digestive system and …. and triggers the protection response. 13
Slide 14: Test Results
TEST RESULTS 14
Slide 15: Successful Trials: Injected ViAqua NPs
1 SUCCESSFUL TRIALS INJECTED VIAQUA NPS Challenge tests against the WSSV virus performed at two different facilities (Arizona and Thailand) showed that injected ViAqua RNA sequences and ViAqua formulated nanoparticles Survival % are highly effective against the virus. ViAqua Untreated + Arizona 87%
Slide 16: Overcome Key Challenges: Aquatic Conditions
2 OVERCOME KEY CHALLENGES AQUATIC CONDITIONS ViAqua nanoparticles are stable in sea and fresh water aquatic environment 16
Slide 17: ViAqua NPs in the Digestive System
3 VIAQUA NPS IN THE DIGESTIVE SYSTEM What we see in this image is the absorption of the nannoparticles into the shrimp cells. Carrier protects RNA from enzymatic degradation in digestive system NPs Absorbed through digestive system to induce desired response to virus 17
Slide 18: Lab Tests: Treatment via Feed
4 LAB TESTS TREATMENT VIA FEED 100 Target efficacy – same 90 Results so far : 50% efficacy as injection 80 in shrimp with feed % Gene Silencing 70 60 Our nanoparticles (NPs), given 50 through feed, enter the shrimp cells and trigger the RNAi 40 mechanism; tests showed 50% 30 silencing of the target
Slide 19: Shrimp Are Only the Beginning
SHRIMP ARE ONLY THE BEGINNING ViAqua platform technology: broad range of applications We can address different viruses in shrimp, and in the future tailor the technology for treating other aquatic animals such as fish and other Crustaceans. 19
Slide 20: ViAqua Advantages
VIAQUA ADVANTAGES First real solution - to date no Delivery platform enables treating treatment for shrimp aquaculture wide range of viruses in shrimp diseases and other shellfish species Simple mass Feed-based components for administration via feed shorter regulatory process Know-how enables develo
Slide 21: ViAqua Benefiting the Grower
VIAQUA BENEFITING THE GROWER Via feed – no addition to work flow Cost effective – only 2 administrations per life cycle Estimate 3%-10% increase in total feed price 21
Slide 22: Team of Experts
TEAM OF EXPERTS Shai Ufaz, Ph.D. Shai Einbinder, Ph.D. Prof. Avi Schroeder, Adi Balter, Ph.D., Co-CEO & Co-Founder Co-CEO & Co-Founder Chief Scientist Project manager Molecular biologist; Marine biologist; Extensive development in Biotechnology engineer; experience in experience in product fields of
Slide 23: RNAi, Vaccines Driving M&A Activity
RNAi, VACCINES DRIVING M&A ACTIVITY Company Acquirer/ Deal Type Year Deal Size License Harris vaccines MERCK Acquisition 2015 NA Vaccines animals and aquaculture PHARMAQ Zoetis Acquisition 2015 $765 million Aquaculture Beeologics Monsanto Acquisition 2011 $130 million RNAi technology plants Rosetta
Slide 24: ViAqua Expanding the Market Opportunity
VIAQUA EXPANDING THE MARKET OPPORTUNITY Vaccines recognized as needed treatment solution Growing pressure to reduce use of antibiotics – will enlarge vaccines market ViAqua Market Potential Currently, aquaculture farmers spend app. 2.5% of revenues on vaccine/disease treatment (Market feedback) 2.5%
Slide 25: Product Development Strategy
PRODUCT DEVELOPMENT STRATEGY FIRST FOCUS Oral delivery of RNAi to treat WSSV virus for shrimp; partner with feed companies to produce and market feed NEXT DEVELOPMENT Oral delivery of RNAi for different shrimp viruses and other shellfish species FUTURE Tailor technology to treat other aquatic diseas
Slide 26: IP Status
IP STATUS US Provisional Patent Application No. 62/327,605 Filed On 26 April 2016 ViAqua Therapeutics Ltd. Inventors: Shai UFAZ et al. TITLE: COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS IN SHRIMPS All the technology presented here was filed as a provisional patent application few months a
Slide 27: Development Milestones 1st Round
DEVELOPMENT MILESTONES 1ST ROUND 2017 2018 2019 Final nanoparticles POC formulation for Gene silencing by oral incorporation to feed delivery with ViAqua feed formulation Successful oral WSSV challenge test - Lab scale Successful oral challenge test for Optimized nanoparticle formulation WSSV - Fiel
Slide 28: Funding
FUNDING Currently raising capital for: Accelerate development Complete successful field trial via feed (Q3 2018) in select shrimp research farms Initiate regulatory process (Q4 2018) Our target is to finish a successful oral challenge field trial in 2 years from now and start the regulatory process
Slide 29: Bringing a Desperately Needed Treatment for Aquaculture Diseases
BRINGING A DESPERATELY NEEDED TREATMENT FOR AQUACULTURE DISEASES Contact: Shai Ufaz Mobile: +972-52-843-0591 Email: shai.u@viaqua-t.com 29
ViAqua Therapeutics — Seed Pitch Deck (December 2016) on 6ix